Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41467-021-21111-9 http://scihub22266oqcxt.onion/10.1038/s41467-021-21111-9 33558507!7870823!33558507     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Commun 2021 ; 12 (1): 844 Nephropedia Template TP {{tp|p=33558507|t=2021. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers |pdf=|usr=}}{{33558507}} gab.com Text Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers JO: Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=33558507 #FOAvip There are only few data concerning persistence of neutralizing antibodies (NAbs) among SARS-CoV-2-infected healthcare workers (HCW). These individuals are particularly exposed to SARS-CoV-2 infection and at potential risk of reinfection. We followed 26 HCW with mild COVID-19 three weeks (D21), two months (M2) and three months (M3) after the onset of symptoms. All the HCW had anti-receptor binding domain (RBD) IgA at D21, decreasing to 38.5% at M3 (p < 0.0001). Concomitantly a significant decrease in NAb titers was observed between D21 and M2 (p = 0.03) and between D21 and M3 (p < 0.0001). Here, we report that SARS-CoV-2 can elicit a NAb response correlated with anti-RBD antibody levels. However, this neutralizing activity declines, and may even be lost, in association with a decrease in systemic IgA antibody levels, from two months after disease onset. This short-lasting humoral protection supports strong recommendations to maintain infection prevention and control measures in HCW, and suggests that periodic boosts of SARS-CoV-2 vaccination may be required. Twit Text FOAVip Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers ????Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=33558507 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33558507 #FOAvip English Wikipedia <ref>{{Cite pmid|33558507}}</ref> Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers #MMPMID33558507 Marot S; Malet I; Leducq V; Zafilaza K; Sterlin D; Planas D; Gothland A; Jary A; Dorgham K; Bruel T; Burrel S; Boutolleau D; Schwartz O; Gorochov G; Calvez V; Marcelin AG Nat Commun 2021[Feb]; 12 (1): 844 PMID33558507show ga There are only few data concerning persistence of neutralizing antibodies (NAbs) among SARS-CoV-2-infected healthcare workers (HCW). These individuals are particularly exposed to SARS-CoV-2 infection and at potential risk of reinfection. We followed 26 HCW with mild COVID-19 three weeks (D21), two months (M2) and three months (M3) after the onset of symptoms. All the HCW had anti-receptor binding domain (RBD) IgA at D21, decreasing to 38.5% at M3 (p < 0.0001). Concomitantly a significant decrease in NAb titers was observed between D21 and M2 (p = 0.03) and between D21 and M3 (p < 0.0001). Here, we report that SARS-CoV-2 can elicit a NAb response correlated with anti-RBD antibody levels. However, this neutralizing activity declines, and may even be lost, in association with a decrease in systemic IgA antibody levels, from two months after disease onset. This short-lasting humoral protection supports strong recommendations to maintain infection prevention and control measures in HCW, and suggests that periodic boosts of SARS-CoV-2 vaccination may be required. |Adult[MESH] |Antibodies, Neutralizing/*immunology[MESH] |Antibodies, Viral/*immunology[MESH] |Binding Sites/immunology[MESH] |COVID-19/*immunology/virology[MESH] |Cell Line, Tumor[MESH] |Female[MESH] |Health Personnel/*statistics & numerical data[MESH] |Humans[MESH] |Immunoglobulin A/immunology[MESH] |Male[MESH] |Middle Aged[MESH] |Protein Binding[MESH] |Receptors, Virus/metabolism[MESH] |SARS-CoV-2/*immunology/physiology[MESH] |Spike Glycoprotein, Coronavirus/immunology/metabolism[MESH]Rapid decline of neutralizing antibodies against SARS-CoV-2 among infe(epmc).pdf DeepDyve Pubget Overpricing